Information Provided By:
Fly News Breaks for June 15, 2018
CRL
Jun 15, 2018 | 07:22 EDT
As previously reported, KeyBanc analyst Donald Hooker upgraded Charles River to Overweight with a $130 price target, telling investors that the stock is one of the best risk-reward stories in the biopharma outsourcing space heading into the second half of 2018. Hooker says Charles offers, "by far, the most comprehensive set of preclinical research products and services for the biopharma industry," positioning it as a strategic outsourcing partner for clients in ways that its rivals cannot.
News For CRL From the Last 2 Days
There are no results for your query CRL
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.